Canopy Growth (CGC) Cash from Discontinued Operations (2022 - 2024)
Canopy Growth (CGC) reported Cash from Discontinued Operations of 297587.4 for Q1 2024, up 100.91% on a YoY basis from 148118.14 in Q2 2023, and down 47.99% sequentially from 572203.18 in Q4 2023.
Canopy Growth (CGC) Cash from Discontinued Operations (2022 - 2024) Analysis & Trends
Canopy Growth (CGC) has 3 years of Cash from Discontinued Operations data on file, last reported at 297587.4 in Q1 2024.
- For the quarter ending Q1 2024, Cash from Discontinued Operations rose 100.91% year-over-year to 297587.4; the trailing twelve-month figure through Mar 2024 stood at 39876575.24 (changed N/A YoY), and the FY2024 full-year result was 39724577.91, up 67.08% from the prior year.
- Cash from Discontinued Operations slipped to 297587.4 in Q1 2024, from 572203.18 in the prior quarter.
- In the past five years, Cash from Discontinued Operations ranged from a high of 572203.18 in Q4 2023 to a low of 49240487.81 in Q4 2022.
- A 3-year average of 20290105.26 and a median of 20373182.91 in 2023 frame the typical range for Cash from Discontinued Operations.
- Across the five-year window, Cash from Discontinued Operations jumped 101.16% in 2023 and surged 100.91% in 2024, its largest moves.
- Tracing CGC's Cash from Discontinued Operations over 3 years: stood at 49240487.81 in 2022, then soared by 101.16% to 572203.18 in 2023, then slumped by 47.99% to 297587.4 in 2024.
- Business Quant data shows CGC's Cash from Discontinued Operations at 297587.4 in Q1 2024, 572203.18 in Q4 2023, and 9142869.77 in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Canopy Growth | 276.52 Mn | 10.60 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 297,587.40 |
| Mar 31, 2024 | 297,587.40 |
| Dec 31, 2023 | 572,203.18 |
| Dec 31, 2023 | 572,203.18 |
| Sep 30, 2023 | -9.14 Mn |
| Sep 30, 2023 | -9.14 Mn |
| Jun 30, 2023 | -31.60 Mn |
| Jun 30, 2023 | -31.60 Mn |
| Mar 31, 2023 | -32.62 Mn |
| Mar 31, 2023 | -32.62 Mn |
| Dec 31, 2022 | -49.24 Mn |
| Dec 31, 2022 | -49.24 Mn |